1887

Chapter 73 : Cytomegalovirus

Authors: Kirsten ST. George, Aki Hoji, Charles R. Rinaldo, Jr.
Content Type: Reference
Publication Year: 2006

Category: Immunology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Cytomegalovirus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap73-1.gif /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap73-2.gif

Abstract:

The major immediate-early (MIE) promoter of cytomegalovirus (CMV) controls production of the immediate-early gene products. The majority of commercially available assays for CMV IgG antibodies use either viral lysate preparations or semipurified viral proteins as antibody binding targets; the sensitivities of these assays do not vary widely. Virus-specific T-cell-modulating activity by both types of dendritic cells (DCs) can be regulated through binding of natural ligands, such as lipopolysaccharides and CpG oligodeoxynucleotides, to tolllike receptors on the DCs. Circulating levels of anti-gB antibody have been shown to be inversely proportional to systemic viral load in human immunodeficiency virus (HIV)-infected patients, and high titers of glycoprotein-specific antibodies correlate with the absence of viral DNA in the blood of bone marrow transplant recipients. This suggests a role for antiglycoprotein antibodies in the prevention of CMV disease and in the modulation of its progression. Preliminary trials with one such mixture have shown promising results, but as many as four doses may be required to generate persistent neutralizing antibody responses. Importantly, seronegative recipients of seropositive kidneys who received this vaccine not only developed humoral and cellular immunity but also were protected from severe CMV disease. Adoptive immunotherapy has been proposed as an alternative to prophylactic treatments with antiviral drugs for the prevention of CMV disease in transplant recipients.

Citation: George K, Hoji A, Rinaldo, Jr. C. 2006. Cytomegalovirus, p 648-657. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch73
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555815905.ch73
1. Adler, S. P.,, S. A. Plotkin,, E. Gonczol,, M. Cadoz,, C. Meric,, J. B. Wang,, P. Dellamonica,, A. M. Best,, J. Zahradnik,, S. Pincus,, K. Berencsi,, W. I. Cox, and , Z. Gyulai. 1999. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. 180: 843– 846.
2. Adult AIDS Clinical Trials Group. 2005. Lymphopro-lifer-ation assay protocol. Immunology Consensus Protocols. http://aactg.s-3.com/pub/download/labmanual/29-ALM-Lymphocyte-Proliferation-Assay.pdf.
3. Alberola, J.,, V. Dominguez,, L. Cardenoso,, J. Lopez-Aldeguer,, M. Blanes,, F. Estelles,, C. Ricart,, A. Pastor,, R. Igual, and , D. Navarro. 1998. Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease. J. Med. Virol. 55: 272– 280.
4. Altman, J. D.,, P. A. Moss,, P. J. Goulder,, D. H. Barouch,, M. G. Heyzer-Williams,, J. I. Bell,, A. J. McMichael, and , M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94– 96.
5. Angulo, R., and , D. A. Fulcher. 1998. Measurement of Candida-specific blastogenesis: comparison of carboxyfluo-rescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression. Cytometry 34: 143– 151.
6. Appay, V.,, R. R. Dunbar,, M. Callan,, P. Klenerman,, G. M. Gillespie,, L. Papagno,, G. S. Ogg,, A. King,, F. Lechner,, C. A. Spina,, S. Little,, D. V. Havlir,, D. D. Richman,, N. Gruener,, G. Pape,, A. Waters,, P. Easterbrook,, M. Salio,, V. Cerundolo,, A. J. McMichael, and , S. L. Rowland-Jones. 2002. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379– 385.
7. Arvin, A. M.,, P. Fast,, M. Myers,, S. Plotkin, and , R. Rabinovich. 2004. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39: 233– 239.
8. Boeckh, M., and , W. G. Nichols. 2003. Immunosuppressive effects of beta-herpesviruses. Herpes 1: 12– 16.
9. Boppana, S. B.,, J. Miller, and , W. J. Britt. 1996. Transplacentally acquired antiviral antibodies and outcome in congenital human cytomegalovirus infection. Viral Immunol. 9: 211– 218.
10. Britt, W. J.,, L. Vugler,, E. J. Butfiloski, and , E. B. Stephens. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64: 1079– 1085.
11. Burrows, S. R.,, R. A. Elkington,, J. J. Miles,, K. J. Green,, S. Walker,, S. M. Haryana,, D. J. Moss,, H. Dunckley,, J. M. Burrows, and , R. Khanna. 2003. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype. J. Immunol. 171: 1407– 1412.
12. Caliendo, A. M.,, K. St. George,, J. Allega,, A. C. Bullotta,, L. Gilbane, and , C. R. Rinaldo. 2002. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J. Clin. Microbiol. 40: 1581– 1586.
13. Chahroudi, A.,, G. Silvestri, and , M. B. Feinberg. 2003. Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates. Methods 31: 120– 126.
14. Chang, L.,, G. A. Gusewitch,, D. B. Chritton,, J. C. Folz,, L. K. Lebeck, and , S. L. Nehlsen-Cannarella. 1993. Rapid flow cytometric assay for the assessment of natural killer cell activity. J. Immunol. Methods 166: 45– 54.
15. Cobb, B. A.,, Q. Wang,, A. O. Tzianabos, and , D. L. Kasper. 2004. Polysaccharide processing and presentation by the MHCII pathway. Cell 117: 677– 687.
16. Collinet, P.,, D. Subtil,, V. Houfflin-Debarge,, N. Kacet,, A. Dewilde, and , F. Puech. 2004. Routine CMV screening during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 114: 3– 11.
17. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30: 115– 133.
18. Eggers, M.,, U. Bader, and , G. Enders. 2000. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J. Med. Virol. 60: 324– 330.
19. Fortunato, E. A.,, A. K. McElroy,, I. Sanchez, and , D. H. Spector. 2000. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol. 8: 111– 119.
20. Fowler, K. B.,, S. Stagno, and , R. F. Pass. 2003. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289: 1008– 1011.
21. Gamadia, L. E.,, R. J. Rentenaar,, P. A. Baars,, E. B. Remmerswaal,, S. Surachno,, J. F. Weel,, M. Toebes,, T. N. Schumacher,, I. J. Ten Berge, and , R. A. van Lier. 2001. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 98: 754– 761.
22. Gamadia, L. E.,, E. M. van Leeuwen,, E. B. Remmerswaal,, S. L. Yong,, S. Surachno,, P. M. Wertheim-van Dillen,, I. J. Ten Berge, and , R. A. van Lier. 2004. The size and pheno-type of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. J. Immunol. 172: 6107– 6114.
23. Gaytant, M. A.,, E. A. Steegers,, B. A. Semmekrot,, H. M. Merkus, and , J. M. Galama. 2002. Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet. Gynecol. Surv. 57: 245– 256.
24. Gilbert, C.,, J. Bestman-Smith, and , G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Update 5: 88– 114.
25. Grangeot-Keros, L.,, M. J. Mayaux,, P. Lebon,, F. Freymuth,, G. Eugene,, R. Stricker, and , F. Dussaix. 1997. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J. Infect. Dis. 175: 944– 946.
26. He, H.,, C. R. Rinaldo, Jr., and , P. A. Morel. 1995. T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development. J. Gen. Virol. 76: 1603– 1610.
27. Huang, X.-L.,, Z. Fan,, C. Kalinyak,, J. W. Mellors, and , C. R. Rinaldo, Jr. 2000. CD8 + T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects. Clin. Diagn. Lab. Immunol. 7: 279– 287.
28. Jin, X.,, M. A. Demoitie,, S. M. Donahoe,, G. S. Ogg,, S. Bonhoeffer,, W. M. Kakimoto,, G. Gillespie,, R. A. Moss,, W. Dyer,, M. G. Kurilla,, S. R. Riddell,, J. Downie,, J. S. Sullivan,, A. J. McMichael,, C. Workman, and , D. F. Nixon. 2000. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J. Infect. Dis. 181: 165– 175.
29. Kline, J. N.,, T. J. Waldschmidt,, T. R. Businga,, J. F. Lemish,, J. V. Weinstock,, P. S. Thome, and , A. M. Krieg. 1998. Modulation of airway inflammation by CpG oligodeoxynu-cleotides in a murine model of asthma. J. Immunol. 160: 2555– 2559.
30. Lacey, S. F.,, D. J. Diamond, and , J. A. Zaia. 2004. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol. Blood Marrow Transplant. 10: 433– 447.
31. Lazzarotto, T.,, B. Guerra,, P. Spezzacatena,, S. Varani,, L. Gabrielli,, P. Pradelli,, F. Rumpianesi,, C. Banzi,, L. Bovicelli, and , M. P. Landini. 1998. Prenatal diagnosis of congenital cytomegalovirus infection. J. Clin. Microbiol. 36: 3540– 3544.
32. Lazzarotto, T.,, S. Varani,, P. Spezzacatena,, P. Pradelli,, L. Potena,, A. Lombardi,, V. Ghisetti,, L. Gabrielli,, D. A. Abate,, C. Magelli, and , M. P. Landini. 1998. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J. Infect. Dis. 178: 1145– 1149.
33. Lore, K.,, M. R. Betts,, J. M. Brenchley,, J. Kuruppu,, S. Khojasteh,, S. Perfetto,, M. Roederer,, R. A. Seder, and , R. A. Koup. 2003. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 171: 4320– 4328.
34. Nicol, D. L.,, A. S. MacDonald,, P. Belitsky,, S. Lee,, A. D. Cohen,, H. Bitter-Suermann,, J. Lowen, and , A. Whalen. 1993. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 55: 841– 846.
35. Nokta, M. A.,, M. I. Hassan,, K. Loesch, and , R. B. Pollard. 1996. Human cytomegalovirus-induced immunosuppres-sion. Relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E2 in human monocytes. J. Clin. Investig. 97: 2635– 2641.
36. Papanicolaou, G. A.,, J. B. Latouche,, C. Tan,, J. Dupont,, J. Stiles,, E. G. Pamer, and , M. Sadelain. 2003. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 102: 2498– 2505.
37. Peggs, K. S.,, S. Verfuerth,, A. Pizzey,, N. Khan,, M. Guiver,, P. A. Moss, and , S. Mackinnon. 2003. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375– 1377.
38. Quinnan, G. V., Jr.,, N. Kirmani,, A. H. Rook,, J. F. Manischewitz,, L. Jackson,, G. Moreschi,, G. W. Santos,, R. Saral, and , W. H. Burns. 1982. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307: 7– 13.
39. Rinaldo, C. R., Jr.,, W. P. Carney,, B. S. Richter,, P. H. Black, and , M. S. Hirsch. 1980. Mechanisms of immuno-suppression in cytomegaloviral mononucleosis. J. Infect. Dis. 141: 488– 495.
40. Rinaldo, C. R., Jr.,, X.-L. Huang,, Z. Fan,, J. B. Margolick,, L. Borowski,, A. Hoji,, C. Kalinyak,, D. K. McMahon,, S. A. Riddler,, W. H. Hildebrand,, R. B. Day, and , J. W. Mellors. 2000. Anti-human immunodeficiency virus type 1 (HIV-1) CD8+ T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J. Virol. 74: 4127– 4138.
41. Sallusto, F.,, D. Lenig,, R. Forster,, M. Lipp, and , A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708– 712.
42. Schoppel, K.,, F. Hassfurther,, W. Britt,, M. Ohlin,, C. A. Borrebaeck, and , M. Mach. 1996. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216: 133– 145.
43. Schoppel, K.,, C. Schmidt,, H. Einsele,, H. Hebart, and , M. Mach. 1998. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis. 178: 1233– 1243.
44. Slobedman, B., and , E. S. Mocarski. 1999. Quantitative analysis of latent human cytomegalovirus. J. Vral. 73: 4806– 4812.
45. Snydman, D. R. 2001. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transplant. Infect. Dis. 3(Suppl. 2): 6– 13.
46. Snydman, D. R.,, B. G. Werner,, B. Heinze-Lacey,, V. R. Berardi,, N. L. Tilney,, R. L. Kirkman,, E. L. Milford,, S. I. Cho,, H. L. Bush, Jr.,, A. S. Levey, et al. 1987. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317: 1049– 1054.
47. Soderberg, C.,, S. Larsson,, B. L. Rozell,, S. Sumitran-Karuppan,, P. Ljungman, and , F. Moller. 1996. Cytomegalovirus-induced CD13-specific autoimmunity—a possible cause of chronic graft-vs-host disease. Transplantation 61: 600– 609.
48. Sokos, D. R.,, M. Berger, and , H. M. Lazarus. 2002. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 8: 117– 130.
49. Springer, K. L., and , A. Weinberg. 2004. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J. Antimicrob. Chemother. 54: 582– 586.
50. St. George, K., and , C. R. Rinaldo, Jr. 1999. Comparison of cytomegalovirus antigenemia and culture assays in patients on and off antiviral therapy. J. Med. Virol. 59: 91– 97.
51. St. George, K.,, D. T. Rowe, and , C. R. Rinaldo, Jr. 2000. Cytomegalovirus, varicella zoster virus and Epstein-Barr virus, p. 410– 449. In S. C. Specter (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, D.C.
52. Trivedi, D.,, R. Y. Williams,, R. J. O’Reilly, and , G. Koehne. 2005. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 105: 2793– 2801.
53. Utz, U.,, W. Britt,, L. Vugler, and , M. Mach. 1989. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J. Vrol. 63: 1995– 2001.
54. Varnum, S. M.,, D. N. Streblow,, M. F. Monroe,, P. Smith,, K. J. Auberry,, L. Pasa-Tolic,, D. Wang,, D. G. Camp,, K. Rodland,, S. Wiley,, W. Britt,, T. Shenk,, R. D. Smith, and , J. A. Nelson. 2004. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J. Vrol. 78: 10960– 10966.
55. Waldrop, S. L.,, C. J. Pitcher,, D. M. Peterson,, V. C. Maino, and , L. J. Picker. 1997. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeo-static mechanism in HIV-associated immunodeficiency. J. Clin. Investig. 99: 1739– 1750.
56. Walter, E. A.,, P. D. Greenberg,, M. J. Gilbert,, R. J. Finch,, K. S. Watanabe,, E. D. Thomas, and , S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333: 1038– 1044.
57. Weill, D. 2001. Role of cytomegalovirus in cardiac allograft vasculopathy. Transplant. Infect. Dis. 3(Suppl. 2): 44– 48.

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error